RP 001
Alternative Names: RP-001Latest Information Update: 28 Dec 2022
At a glance
- Originator RetiPharma
- Class Eye disorder therapies; Neuropeptides; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal detachment